Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

NCT05355753 is registered in ClinicalTrials.gov with C4 Therapeutics, Inc. as lead sponsor.

NCT NCT05355753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05355753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
Lead sponsor
C4 Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 25, 2022
Completion date
December 19, 2023
Enrollment
49 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma, synovial sarcoma